Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now

Summit Therapeutics faces downside risk if its lead candidate does not secure regulatory approval later this year; shares could decline roughly 1-3% on an adverse outcome. Conversely, Madrigal Pharmaceuticals and Axsome Therapeutics could rally on favorable developments or sector re-rating, potentially moving a similar magnitude. Action: monitor regulatory milestones, clinical-readout timelines and short-term positioning around these event windows.

Analysis

Summit Therapeutics faces downside risk if its lead candidate does not secure regulatory approval later this year; shares could decline roughly 1-3% on an adverse outcome. Conversely, Madrigal Pharmaceuticals and Axsome Therapeutics could rally on favorable developments or sector re-rating, potentially moving a similar magnitude. Action: monitor regulatory milestones, clinical-readout timelines and short-term positioning around these event windows.